Savara Inc. (NASDAQ:SVRA) Stock Has Average Target Price of $10.00 According to Brokerages

Shares of Savara Inc. (NASDAQ:SVRA) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $10.00.

Several brokerages recently weighed in on SVRA. Wall Street Zen cut shares of Savara from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th.

Savara Stock Performance

NASDAQ:SVRA opened at $5.07 on Friday. The company has a market capitalization of $1.04 billion, a PE ratio of -8.74 and a beta of 0.25. The company has a 50 day simple moving average of $5.45 and a two-hundred day simple moving average of $5.44. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. Savara has a fifty-two week low of $3.34 and a fifty-two week high of $7.01.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Research analysts anticipate that Savara will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On Savara

Several large investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. bought a new position in Savara during the first quarter worth about $57,000. Sequoia Financial Advisors LLC purchased a new position in shares of Savara in the second quarter worth about $69,000. E Fund Management Co. Ltd. bought a new stake in shares of Savara in the second quarter valued at approximately $77,000. Inceptionr LLC bought a new stake in shares of Savara in the first quarter valued at approximately $84,000. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Savara during the 2nd quarter valued at approximately $87,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s primary focus is autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which abnormal accumulation of surfactant in the lungs can impair breathing and oxygen exchange.

Savara’s lead product candidate is molgramostim, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is designed to help restore the function of pulmonary alveolar macrophages, the immune cells responsible for clearing excess surfactant from the lungs.